Clinical Trials Logo

Clinical Trial Summary

A previous phase II trial entitled Treatment of Follicular non-Hodgkin's Lymphoma with High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy with Rituximab and Alpha Interferon was conducted at the Odette Cancer Centre between 2005 and 2012. The primary objectives of this previous trial was to assess progression free survival and overall survival. Of the 36 patients in this trial, approximately 18 remain in remission. In this new follow up trial, follow up data will prospectively be collected on patients who provide informed consent to do so.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03087929
Study type Observational
Source Sunnybrook Health Sciences Centre
Contact
Status Completed
Phase N/A
Start date September 20, 2013
Completion date March 15, 2017

See also
  Status Clinical Trial Phase
Completed NCT01950273 - Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma Phase 1
Completed NCT00930514 - A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma Phase 1
Completed NCT02472756 - Open, Noninterventional Trial of MabThera in Combination With Chemotherapy (CVP, CHOP or FCM) in Patients With Relapsed/Refractory Follicular Lymphoma N/A
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00193492 - A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma Phase 2
Withdrawn NCT00092274 - Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma Phase 1/Phase 2
Terminated NCT02413489 - An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma Phase 2
Completed NCT00915096 - Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma
Recruiting NCT05849857 - Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries Phase 2
Recruiting NCT05410418 - Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma Phase 2
Terminated NCT01609036 - An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma N/A
Completed NCT01234766 - Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma Phase 2
Completed NCT00849147 - Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Phase 2
Terminated NCT00384111 - Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) Phase 3
Completed NCT03682796 - Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma Phase 1
Recruiting NCT04982471 - Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study
Active, not recruiting NCT02996773 - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine Phase 1
Terminated NCT00562965 - Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) Phase 3
Active, not recruiting NCT00317096 - FCM Versus R-FCM Followed by R-Maintenance or Observation Only Phase 3
Not yet recruiting NCT06213636 - Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). Phase 1/Phase 2